Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases

被引：0
|
作者：
Crino, L. [1 ]
Horn, L. [2 ]
Felip, E. [3 ]
Frontera, O. Aren [4 ]
Burgio, M. [1 ]
Waterhouse, D. [5 ]
Blumenschein, G. [6 ]
Barlesi, F. [7 ]
Garassino, M. [8 ]
Holgado, E. [9 ]
Antonia, S. [10 ]
Spigel, D. [11 ]
Gainor, J. [12 ]
Gettinger, S. [13 ]
Geese, W. [14 ]
Li, A. [14 ]
Healey, D. [14 ]
Ready, N. [15 ]
机构：
[1] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori Irst, Meldola, Italy
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] Hosp Univ Vall dHebron, Barcelona, Spain
[4] Ctr Int Estudios Clin, Santiago, Chile
[5] Oncol Hematol Care Ohc Us Oncol, Cincinnati, OH USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Aix Marseille Univ, AP HM, Marseille, France
[8] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[9] Hosp Madrid, Madrid, Spain
[10] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[11] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Nashville, TN USA
[12] Massachusetts Gen Hosp, Boston, MA 02114 USA
[13] Yale Comprehens Canc Ctr, New Haven, CT USA
[14] Bristol Myers Squibb, Princeton, NJ USA
[15] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Nivolumab; non-small cell lung cancer;
D O I：
10.1016/j.jtho.2017.09.1703
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.07-012
引用
收藏
页码：S2302 / S2302
页数：1
相关论文
共 50 条
  • [31] Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients
    Kitadai, Rui
    Yoshimura, Akihiro
    Yamada, Tadaaki
    Okuma, Yusuke
    Takeda, Takayuki
    Kanematsu, Takanori
    Uchino, Junji
    Nishioka, Yasuhiko
    Takayama, Koichi
    CANCER RESEARCH, 2020, 80 (16)
  • [32] Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients
    Yoshimura, Akihiro
    Yamada, Tadaaki
    Okuma, Yusuke
    Kitadai, Rui
    Takeda, Takayuki
    Kanematsu, Takanori
    Goto, Hisatsugu
    Yoneda, Hiroto
    Harada, Taishi
    Kubota, Yutaka
    Yamada, Takahiro
    Date, Koji
    Shiotsu, Shinsuke
    Nagata, Kazuhiro
    Chihara, Yusuke
    Kaneko, Yoshiko
    Uchino, Junji
    Nishioka, Yasuhiko
    Takayama, Koichi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (04) : 450 - +
  • [33] A phase IINCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer
    Molina, Julian R.
    Nikcevich, Daniel
    Hillman, Shauna
    Geyer, Susan
    Drevyanko, Timothy
    Jett, James
    Verdirame, Joseph
    Tazelaar, Henry
    Rowland, Kendrith
    Wos, Edward
    Kutteh, Leila
    Nair, Suresh
    Fitch, Tom
    Flynn, Patrick
    Stella, Philip
    Adjei, Alex A.
    CANCER INVESTIGATION, 2006, 24 (04) : 382 - 389
  • [34] Docetaxel in advanced non-small cell lung cancer
    Wakelee, H
    Ramalingam, S
    Belani, CP
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) : 13 - 24
  • [35] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Tu, Haiyan
    Wu, Lin
    Feng, Jifeng
    Zhang, Yiping
    Luft, Alexander Valeriercich
    Zhou, Jianying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Baudelet, Christine
    Li, Zoe
    Chang, Jianhua
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study
    Wang, Yang
    Hao, Qianyun
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Zhang, Jie
    Chen, Xiaoling
    Ma, Xiangjuan
    Tian, Guangming
    Han, Jindi
    Han, Sen
    Wu, Di
    Long, Jieran
    Zhang, Ziran
    Fang, Jian
    ANTI-CANCER DRUGS, 2024, 35 (05) : 412 - 417
  • [37] Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017
    Reck, M.
    Coon, C.
    Taylor, F.
    DeRosa, M.
    Penrod, J. R.
    Dastani, H.
    Orsini, L.
    Gralla, R. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S599 - S600
  • [38] Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017
    Reck, M.
    Coon, C.
    Taylor, F.
    Derosa, M.
    Penrod, J. R.
    Dastani, H.
    Orsini, L.
    Gralla, R. J.
    ANNALS OF ONCOLOGY, 2015, 26 : 141 - 141
  • [39] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02): : 123 - 135
  • [40] Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2018, 13 (03) : 399 - 407
12345